Janssen (J&J)
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Janssen (J&J) concentrates its licensing activity in Oncology, InfectiousDisease, and Immunology. Janssen (J&J) pays a 1.39x premium over market median. Their most common deal structure is License, with an average disclosed value of $1.8B. Most recent activity: 2026.
Pipeline coverage & gaps
Janssen (J&J) has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $43M | $2.2B |
| Collaboration | 6 | $118M | $1.8B |
| Acquisition | 2 | $658M | $833M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | LCB84 | LegoChem Biosciences | — | unknown | — | $1.7B |
| 2026 | JNJ-3989 / ARO-HBV | Arrowhead Pharmaceuticals | hepatitis B | unknown | — | $3.7B |
| 2024 | NM26 | Numab/Yellow Jersey | atopic dermatitis | phase_2 | $1.3B | $1.3B |
| 2024 | icotrokinra (JNJ-2113) | Protagonist Therapeutics | psoriasis | phase_2 | $300M | $630M |
| 2023 | RPGR Product | MeiraGTx Holdings plc | x-linked retinitis pigmentosa | phase_3 | $65M | $415M |
| 2023 | NBTXR3 | Nanobiotix SA | locally advanced head and neck cancer | phase_3 | $30M | $2.6B |
| 2023 | NBTXR3 | Nanobiotix S.A. | locally advanced soft-tissue sarcoma | phase_3 | $60M | $2.6B |
| 2023 | CD388 | Cidara Therapeutics | influenza | phase_2 | — | $692M |
| 2023 | NBTXR3 (JNJ-1900) | Nanobiotix | locally advanced head and neck cancer | phase_3 | $30M | $1.9B |
| 2023 | hepatitis_b | Arcturus Therapeutics | hepatitis_b | preclinical | $75M | $1.5B |
| 2022 | P-BCMA-ALLO1 | Poseida Therapeutics | multiple myeloma | phase_1 | $110M | $6.0B |
| 2022 | ADC platform (up to three Janssen-selected targets) | Mersana Therapeutics | — | discovery | $40M | $1.1B |
| 2022 | Dolasynthen ADC platform | Mersana Therapeutics, Inc. | solid_tumor | discovery | $40M | $1.1B |
| 2021 | — | F-star Therapeutics, Inc. | — | discovery | $18M | $1.4B |
| 2021 | Plamotamab (CD20×CD3 T-cell engager program) | Xencor, Inc. | DLBCL / lymphoma | phase_1 | $100M | $1.3B |
How this is computed
For each Janssen (J&J) deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.388, clamped to [0.7, 1.5].